Non-Small Cell Lung Cancer
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
Researchers Analyze Olaparib, Pemetrexed as Maintenance Therapy Additions to Pembrolizumab for NSCLC
Pembrolizumab plus maintenance olaparib was not shown to improve survival in patients with metastatic nonsquamous NSCLC.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Durvalumab does not improve overall survival compared to chemotherapy when used as a first-line treatment for mNSCLC.
The updated analysis was presented at the Society for Immunotherapy in Cancer 2024 Annual Meeting.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Officials Provide Update on Datopotamab Deruxtecan Biologics License Application for NSCLC Treatment
A prior BLA has been voluntarily withdrawn and a new BLA has been submitted for US accelerated approval.
The real-world study is the first to provide an overview of EGFR mutations and subtype prevalence in patients with NSCLC.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
The research, presented at SITC 2024, showed the deep learning approach could help predict ICI response in NSCLC.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.